Heritage, Apotex plan to pay $49.1 million to settle drug pricing scheme allegations
Two pharmaceutical companies will pay $49.1 million to resolve allegations that they inflated prices, reduced competition and restricted access to generic drugs, Attorney General Josh Kaul said Thursday.
To access this content, you must purchase a Premium membership, or log in if you are a member.
